RVPH (Reviva Pharmaceuticals, Inc.) Forward P/S Multiple
Financial pressure from R&D costs and the anticipation of regulatory approval are creating volatility, which this forward P/S chart for Reviva Pharmaceuticals (RVPH) captures. The mark serves as a current indicator of market expectations. Growth potential is based on the development of safe psychotropics with minimal side effects, although geopolitics could disrupt component logistics and the timelines for overseas trials.
Summary analytical data breakdowns for Reviva Pharmaceuticals (RVPH)
- market price and analyst price targets:
- business market valuation indicators:
- issuer book value statistics:
- debt and solvency information:
Debt to Equity Reviva Pharmaceuticals|RVPH - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital revivapharma.com|RVPH - Company Aggregate Debts|Debts to Book Capitalization Reviva Pharmaceuticals Holdings Inc.|RVPH - Company Long-Term Liabilities|Company Short-Term Debts Reviva Pharmaceuticals|Quick Liquidity Indicator revivapharma.com
- financial results and valuation multiples details:
RVPH - Net Profit|Future Profit Reviva Pharmaceuticals|RVPH - Market Price to Net Income Ratio|Forward P/E Multiple revivapharma.com|RVPH - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Reviva Pharmaceuticals Holdings Inc.|RVPH - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Reviva Pharmaceuticals|RVPH - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months revivapharma.com|RVPH - Earnings per share growth in current year|Net earnings per share growth forecast for next year Reviva Pharmaceuticals
- total revenue and sales volume data:
Fundamental company analysis:Reviva Pharmaceuticals, Inc. RVPH
Forward P/S determines the market value of a business relative to projected annual sales, allowing for an assessment of whether the current capitalization is fair without the delays of quarterly reporting. Analyzing the expected P/S ratio helps determine the extent to which the market has overvalued Reviva Pharmaceuticals (RVPH) ahead of the neuroleptic's approval, given that safety costs are already priced in while revenue will only materialize following regulatory approval.
Competitors of Reviva Pharmaceuticals (RVPH)
Forward P/S Multiple BIIB (Biogen Idec)|Market Cap to Expected Sales Ratio Neurocrine Corp (NBIX)|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Therapeutics)|ACAD: Forward P/S Multiple|Xenon Pharmaceuticals Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Viking Pharma|SUPN: Forward Price to Sales|Forward P/S Multiple CPRX|Forward P/S Multiple denalitherapeutics.com (DNLI)|Forward P/S Multiple HRMY (Harmony Biosciences Inc)|Market Cap to Expected Sales Ratio Biohaven (BHVN)|Amylyx Corp - Forward P/S Multiple|TRVI - Forward P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Price-to-Projected Revenue Ratio|AVXL - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CeriBell|Forward P/S Multiple Prothena Corporation plc|Price-to-Projected Revenue Ratio Alector Therapeutics (ALEC)|Annexon Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio omeros.com OMER|neurogene.com (NGNE) - Market Cap to Future Revenue Ratio|acimmune.com - Forward P/S Multiple|Voyager Therapeutics Inc (VYGR) - Forward Price-to-Revenue Multiple|Neumora Corp (NMRA) - Price-to-Projected Revenue Ratio|Scilex Holding Company, Inc. (SCLX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TVGN|Market Cap to Future Revenue Ratio Alpha Cognition Inc. ACOG|Price-to-Projected Revenue Ratio cogrx.com (CGTX)|Market Cap to Expected Sales Ratio Inhibikase Therapeutics, Inc.|Forward P/S Multiple SAVA (Cassava Sciences Inc)|Forward P/S Multiple Assertio Holdings, Inc. ASRT|COYA - Price-to-Projected Revenue Ratio|Projected Price to Revenue Vistagen (VTGN)|OVID: Forward P/S Multiple|Market Cap to Future Revenue Ratio Acumen Pharmaceuticals Inc. (ABOS)|Forward Price-to-Revenue Multiple CRVO|Market Cap to Projected Revenue ATHE (Alterity Therapeutics)|Price-to-Projected Revenue Ratio Clene Nanomedicine (CLNN)|PEPG (PepGen) - Forward Price to Sales|Price-to-Projected Revenue Ratio Jupiter Neurosciences Inc JUNS|Forward Price to Sales RLMD|ANVS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Grace Therapeutics Inc|AIFF: Forward P/S Multiple|Market Cap to Future Revenue Ratio Klotho Neurosciences Inc (KLTO)|Price-to-Projected Revenue Ratio neurosense-tx.com|Forward Price-to-Revenue Multiple metaviatx.com (MTVA)|Forward P/S Multiple NRXS|HSDT - Market Cap to Future Revenue Ratio|Passage Bio, Inc. - Forward Price-to-Revenue Multiple|bionomics.com.au (NEUP) - Market Cap to Future Revenue Ratio|Minerva - Forward P/S Multiple|Forward Price to Sales ATHA (Athira Pharma Inc)|ADXN: Forward P/S Multiple|Market Cap to Projected Revenue ALZN|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|PTIX (Protagenic Therapeutics) - Price to Expected Revenue Ratio|Forward P/S Multiple KTTA|Market Cap to Expected Sales Ratio Cortigent|Forward P/S Multiple ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Price-to-Projected Revenue Ratio|Cara Therapeutics Inc. - Forward P/S Multiple|Chromocell Therapeutics (CHRO) - Forward Price-to-Revenue Multiple|ELYM: Forward P/S Multiple|Forward Price-to-Revenue Multiple Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Forward P/S Multiple|Marinus - Future Price to Revenue|Forward P/S Multiple NKGN|NRBO (NeuroBo Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple SAGE (Sage Therapeutics Inc)|Market Cap to Expected Sales Ratio Synaptogenix Inc. (SNPX)|TRVN - Price-to-Projected Revenue Ratio|vigilneuro.com (VIGL) - Forward Price-to-Revenue Multiple|WENA: Forward P/S Multiple|Cerevel Therapeutics, Inc. (CERE) - Forward P/S Multiple
